These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26018247)

  • 1. Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis.
    Jha S; Wang Z; Laucis N; Bhattacharyya T
    J Bone Miner Res; 2015 Dec; 30(12):2179-87. PubMed ID: 26018247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.
    Kim SY; Schneeweiss S; Katz JN; Levin R; Solomon DH
    J Bone Miner Res; 2011 May; 26(5):993-1001. PubMed ID: 21542002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
    Wang Z; Ward MM; Chan L; Bhattacharyya T
    Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
    Pazianas M; Abrahamsen B; Wang Y; Russell RG
    Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
    Abrahamsen B; Eiken P; Eastell R
    J Clin Endocrinol Metab; 2010 Dec; 95(12):5258-65. PubMed ID: 20843943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.
    Rizzoli R; Akesson K; Bouxsein M; Kanis JA; Napoli N; Papapoulos S; Reginster JY; Cooper C
    Osteoporos Int; 2011 Feb; 22(2):373-90. PubMed ID: 21085935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.
    Park-Wyllie LY; Mamdani MM; Juurlink DN; Hawker GA; Gunraj N; Austin PC; Whelan DB; Weiler PJ; Laupacis A
    JAMA; 2011 Feb; 305(8):783-9. PubMed ID: 21343577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
    Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ;
    N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial.
    Adachi JD; Lyles K; Boonen S; Colón-Emeric C; Hyldstrup L; Nordsletten L; Pieper C; Recknor C; Su G; Bucci-Rechtweg C; Magaziner J
    Calcif Tissue Int; 2011 Dec; 89(6):427-33. PubMed ID: 22038744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.
    Wang Z; Bhattacharyya T
    J Bone Miner Res; 2011 Mar; 26(3):553-60. PubMed ID: 20814954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration.
    Safford MM; Barasch A; Curtis JR; Outman R; Saag K
    J Clin Rheumatol; 2014 Oct; 20(7):357-62. PubMed ID: 25275761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture.
    Kim SC; Kim DH; Mogun H; Eddings W; Polinski JM; Franklin JM; Solomon DH
    J Bone Miner Res; 2016 Aug; 31(8):1536-40. PubMed ID: 26969902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort.
    Won SH; Ahn S; Ji E; Park JW; Kim JK; Lee YK
    J Korean Med Sci; 2020 Jun; 35(25):e193. PubMed ID: 32597040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral bisphosphonates are associated with reduced mortality after hip fracture.
    Beaupre LA; Morrish DW; Hanley DA; Maksymowych WP; Bell NR; Juby AG; Majumdar SR
    Osteoporos Int; 2011 Mar; 22(3):983-91. PubMed ID: 21052642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
    Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
    N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.
    Puhaindran ME; Farooki A; Steensma MR; Hameed M; Healey JH; Boland PJ
    J Bone Joint Surg Am; 2011 Jul; 93(13):1235-42. PubMed ID: 21776577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Oral Bisphosphonate Drug Holiday on Mortality Following Hip Fracture.
    Leung MTY; Turner JP; Marquina C; Ilomaki J; Tran T; Bell JS
    J Clin Endocrinol Metab; 2024 Oct; 109(11):2793-2801. PubMed ID: 38630464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry.
    Lee YK; Ha YC; Park C; Yoo JJ; Shin CS; Koo KH
    Osteoporos Int; 2013 Feb; 24(2):707-11. PubMed ID: 22618268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healing Time and Complications in Operatively Treated Atypical Femur Fractures Associated With Bisphosphonate Use: A Multicenter Retrospective Cohort.
    Bogdan Y; Tornetta P; Einhorn TA; Guy P; Leveille L; Robinson J; Bosse MJ; Haines N; Horwitz D; Jones C; Schemitsch E; Sagi C; Thomas B; Stahl D; Ricci W; Brady M; Sanders D; Kain M; Higgins TF; Collinge C; Kottmeier S; Friess D
    J Orthop Trauma; 2016 Apr; 30(4):177-81. PubMed ID: 26709814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.